Revive BioShield II: Bring Big Pharma Back Into Medical Countermeasures
This article was originally published in RPM Report
Executive Summary
The legislative architect of BioShield II proposal that failed to make it into law in 2005 argues that the proposal remains the best approach for bringing experienced, well-funded medical product companies into the effort to protect the nation against bioterror attacks -- from other governments and from nature.
You may also be interested in...
Rx Countermeasures: HHS Launching "Pivotal Studies" To Engage Industry
HHS is hoping to redefine its relationship with biotech and pharmaceutical firms that are developing Rx countermeasures though a series of "pivotal studies" under which government works more closely with industry at the beginning stages of development